Rapport Therapeutics (RAPP) Research & Development (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Research & Development of $32.7 million for Q1 2026, up 67.16% year-over-year from $19.6 million in Q1 2025, and up 8.12% quarter-over-quarter from $30.3 million in Q4 2025.
Rapport Therapeutics (RAPP) Research & Development (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Research & Development for 4 consecutive years, with $32.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 67.16% year-over-year to $32.7 million; the TTM figure through Mar 2026 stood at $107.9 million (up 58.72% YoY), while the FY2025 annual figure was $94.8 million, up 55.56% from the prior year.
- Research & Development grew to $32.7 million in Q1 2026 per RAPP's latest filing, from $30.3 million in the prior quarter.
- Across five years, Research & Development topped out at $32.7 million in Q1 2026 and bottomed at $4.7 million in Q2 2023.
- Historically, Research & Development has averaged $17.7 million across 4 years, with a median of $16.4 million in 2024.
- Annual changes were most pronounced in 2024 — Research & Development surged 232.32% — and 2025, when it jumped 43.34%.
- Rapport Therapeutics' Research & Development stood at $11.8 million in 2023, then surged by 45.77% to $17.2 million in 2024, then soared by 75.93% to $30.3 million in 2025, then increased by 8.12% to $32.7 million in 2026.
- Business Quant data shows RAPP's Research & Development at $32.7 million in Q1 2026, $30.3 million in Q4 2025, and $22.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | 51.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.41 Mn |
| Mar 31, 2026 | 32.72 Mn |
| Dec 31, 2025 | 30.26 Mn |
| Sep 30, 2025 | 22.28 Mn |
| Jun 30, 2025 | 22.68 Mn |
| Mar 31, 2025 | 19.57 Mn |
| Dec 31, 2024 | 17.20 Mn |
| Sep 30, 2024 | 15.54 Mn |
| Jun 30, 2024 | 15.69 Mn |
| Mar 31, 2024 | 12.50 Mn |
| Dec 31, 2023 | 11.80 Mn |
| Sep 30, 2023 | 7.58 Mn |
| Jun 30, 2023 | 4.72 Mn |